Copenhagen, Denmark, 10 September 2024 - Xellia Pharmaceuticals ('Xellia') is pleased to announce that it has completed the divestment of its US-based institutional activities to Hikma Pharmaceuticals (Hikma), a leading global supplier of generic injectables, following clearance under applicable US antitrust laws.
The transaction includes the Cleveland, Ohio, USA manufacturing site, the in-market institutional, commercial portfolio based in Chicago, Illinois, USA, the drug product R&D pipeline, and the majority of the R&D activities in Zagreb, Croatia.
The divestment follows a strategic decision to focus on the manufacturing and commercializing of fermentation-based anti-infective APIs and a selected range of finished dose forms for the global B2B markets.
Michael Kocher, CEO at Xellia Pharmaceuticals, said:
“Completing the transaction with Hikma is a defining milestone in the transformation journey we embarked on less than a year ago. By focusing on our core strengths, we are positioning Xellia for a robust and prosperous future, enabling us to continue to deliver life-saving products to patients worldwide.”
For more information, please contact:
Xellia Pharmaceuticals
Andreas Hylleberg Mølleskov, Director, Communications, Branding and Public Affairs
Andreas.Molleskov@xellia.com